Stated revs are going to be over 10 million for the year .. No kiddin the 9 months was over 11 ..Whats the point other than a pump..
Nine month highlights (for the period from 1/1/13 to 9/30/13) included:
• Sales increased to $11,495,871 from $9,781,990 for 2012, an increase of 17.5%
• Gross Profit increased to $3,673,766 from $2,997,775 last year, a 22.5% increase
• Net Income for the nine month period increased to $110,090 or $0.01 EPS compared to a net loss of $273,248 or a .02 EPS loss for the first nine months of 2012
Wecome back..Now that your out and about..Who was the poster that found the info about you?? Cmon.. Name address phone etc.. Called you .That dude??. WHO IS IT????
Is it possible they do a nice acquisition that's has a lot of unused NOL's that they can take advantage of.. Your thoughts.. Makes sense to me .. Rules do have some restrictions.. Just have to find the right company at thr best value..
Buy it pretty soon or you're gonna pay 10...Its getting ready to go a little .. drying up some here..thanks...Get a bunch now ..and don't pay over 9.51..
CMO .. Material event has to be reported within get it.. If they let him go Friday ,which is the normal day of layoffs firing etc.....Get it???? The bigger question was he is he a mole????
How would you feel if you sold at the bottom on some BS recommendation of a stupid short ..I was trying to calm people and tell them to add.. That's why I am the truth.. Just thought it was overdone and under 9 looked very reasonable to me..Still does
Finanza.......Now we know the price of the converts.. Dilution is about 12-13% .. And its way off in the future.. Its all good .. Hope you added finanza
It's "lull", lol.
WE be goin' to 44 TODAY. UBNT chart never stays flat like it did for most of the day Friday.
Besides I got a margin call, so this POS BETTER move up!
your ...oh wait you're.........a terrible trader..doesn't change facts ..LOL
Looks like a dead end ..
Update on Bexarotene for Alzheimer's
Email This Entry
Posted by Derek
Here's a follow-up on the news that bexarotene might be useful for Alzheimer's. Unfortunately, what seems to be happening is what happens almost every time that the word "Alzheimer's" is mentioned along with a small molecule. As Nature reports here, further studies are delivering puzzling results.
The original work, from the Landreth lab at Case Western, reported lower concentrations of soluble amyloid, memory improvements in impaired rodents, and (quite strikingly), clearance of large amounts of existing amyloid plaque in their brain tissue. Now four separate studies (1, 2, 3, 4) are out in the May 24th issue of Science, and the waters are well muddied. No one has seen the plaque clearance, for one thing. Two groups have noted a lowering of soluble amyloid, though, and one study does report some effects on memory in a mouse model.
So where are we? Here's Landreth himself on the results:
It was our expectation other people would be able to repeat this,” says Landreth about the results of the studies. “Turns out that wasn’t the case, and we fundamentally don’t understand that.” He suggests that the other groups might have used different drug preparations that altered the concentration of bexarotene in the brain or even changed its biological activity.
In a response published alongside the comment articles, Landreth emphasizes that some of the studies affirm two key conclusions of the original paper: the lowering of soluble β-amyloid levels and the reversal of cognitive deficits. He says that the interest in plaques may even be irrelevant to Alzheimer’s disease.
That last line of thought is a bit dangerous. It was, after all, the plaque clearance that got this work all the attention in the first place, so to claim that it might not be that big a deal once it failed to repeat looks like an exercise in goalpost-shifting. There might be something here, d